Morphological changes after cranial fractionated photon radiotherapy: Localized loss of white matter and grey matter volume with increasing dose

S.H.J. Nagtegaal a, S David a, E.E. van Grinsven a, M.J.E. van Zandvoort b, E. Seravalli a, T. J Snijders b, M.E.P. Philippens a, J.J.C. Verhoeff a, b, *

a Department of Radiation Oncology, University Medical Center, HP Q 00.3.11, PO Box 85500, 3508 GA Utrecht, the Netherlands
b UMC Utrecht Brain Center, Department of Neurology & Neurosurgery, University Medical Center, HP L, 01.310, PO Box 85500, 3508 GA Utrecht, the Netherlands

A B S T R A C T

Purpose: Numeroubrain MR imaging studies have been performed to understand radiation-induced cognitive decline. However, many of them focus on a single region of interest, e.g. cerebral cortex or hippocampus. In this study, we use deformation-based morphometry (DBM) and voxel-based morphometry (VBM) to measure the morphological changes in patients receiving fractionated photon RT, and relate these to the dose. Additionally, we study tissue specific volume changes in white matter (WM), grey matter (GM), cerebrospinal fluid and total intracranial volume (TIV).

Methods and materials: From our database, we selected 28 patients with MRI of high quality available at baseline and 1 year after RT. Scans were rigidly registered to each other, and to the planning CT and dose file. We used DBM to study non-tissue-specific volumetric changes, and VBM to study volume loss in grey matter. Observed changes were then related to the applied radiation dose (in EQD2). Additionally, brain tissue was segmented into WM, GM and cerebrospinal fluid, and changes in these volumes and TIV were tested.

Results: Performing DBM resulted in clusters of dose-dependent volume loss 1 year after RT seen throughout the brain. Both WM and GM were affected; within the latter both cerebral cortex and subcortical nuclei show volume loss. Volume loss rates ranging from 5.3 to 15.3%/30 Gy were seen in the cerebral cortical regions in which more than 40% of voxels were affected. In VBM, similar loss rates were seen in the cortex and nuclei. The total volume of WM and GM significantly decreased with rates of 5.8% and 2.1%, while TIV remained unchanged as expected.

Conclusions: Radiation-induced brain injury is a phenomenon experienced after radiotherapy (RT) for brain tumors [1,2]. Anatomical and functional changes can lead to cognitive impairments, ranging from mild symptoms to severe dementia-like states, and occur in 50–90% of cases [1,2]. This phenomenon is seen in patients receiving treatment for primary brain tumors, as well as those receiving whole-brain radiotherapy for brain metastases and prophylactic cranial radiotherapy.

Abbreviations: CAT12, Computational Anatomy Toolbox 12; CSF, cerebrospinal fluid; CT, computed tomography; DBM, deformation based morphometry; FWER, family-wise error rate; GM, grey matter; IMPT, intensity modulated proton therapy; MNI, Montreal Neurological Institute; MRI, magnetic resonance imaging; PALM, permutation analysis of linear models; PTV, planning target volume; RT, radiotherapy; SNR, signal to noise ratio; TFCE, Threshold-Free Cluster Enhancement; TFE, turbo fast echo; TIV, total intracranial volume; VBM, voxel-based morphometry; VMAT, volumetric modulated arc therapy.

* Corresponding author at: Radiation Oncologist, Department of Radiation Oncology, University Medical Center, PO Box 85500, 3508 GA Utrecht, the Netherlands. E-mail address: J.J.C.Verhoeff-10@umcutrecht.nl (J.J.C. Verhoeff).

https://doi.org/10.1016/j.ctro.2021.08.010
Received 7 January 2021; Received in revised form 4 August 2021; Accepted 25 August 2021
Available online 29 August 2021
2405-6308/© 2021 The Author(s). Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
One such technique is deformation based morphometry (DBM) [11,12]. Here, the entire brain is analyzed, and no pre-specification of tissue type or brain region is made beforehand. Pre-RT and post-RT MRI scans are non-linearly registered to the stereotactic Montreal Neurological Institute (MNI) brain template, and the transformations applied during these steps are recorded as 3D deformation fields. These fields can be used to determine the volume changes after RT, which in turn can be related to the received dose. Investigations in epilepsy and related research have successfully applied the DBM method previously [13,14]. The DBM model can be extended by adding explicit tissue segmentations. Healthy brain tissue can be segmented into WM, GM and cerebrospinal fluid (CSF). To study the GM in more detail, GM segments can be fused with 3D deformation fields in order to perform a tissue-specific investigation, often referred to as voxel-based morphometry (VBM) [15]. In VBM, the changes in each voxel between pre-RT and post-RT GM maps are measured for each patient. Next to global changes in brain tissue volume, one may also study the sum of GM, WM and CSF volumes, which together make up the total intracranial volume (TIV) [16]. VBM is a commonly applied tool in neuroscientific studies on aging [17,18], while TIV is more commonly used to study brain development [19].

In this study, we use DBM and VBM to measure the morphological changes in glioma patients receiving fractionated photon RT, and relate these to the dose. Additionally, we study gross volume changes in WM, GM, CSF and TIV.

Methods

Patient selection and data collection

We retrospectively identified scans from patients treated with RT for grade II-IV glioma at the department of Radiation Oncology in 2016 and 2017. This specific period was chosen because all glioma patients were scanned on the same MRI scanner, using the same protocols. As the MRI protocol was updated after 2017, more recently treated patients were not included to maintain data homogeneity. Patients were eligible for inclusion when the following criteria were met: treatment planning CT and MRI present, and of sufficient resolution (see below); progression free survival of at least 270 days after RT; at least 1 follow-up MRI between 270 days and 360 days after RT present, and of sufficient resolution.

Clinical MRI and CT scans made for RT treatment planning were extracted from patient records and anonymized, along with all follow-up MRIs, and clinical and demographic characteristics. Informed consent for this retrospective study was waived by our institutional review board.

Image acquisition

For every patient the planning CT and pre-RT MRI were collected, as well as all available follow-up MRIs. MR images were acquired on the same 3 T scanner (Philips Ingenia, Philips Medical Systems, Best, The Netherlands) as part of routine clinical care. T1-weighted MR images were acquired with a 3D spoiled gradient (TFE) sequence without gadolinium enhancement with the following parameters: TR = 8.1 ms, TE = 3.7 ms, flip angle = 8°, 213 axial slices, matrix: 207 × 289, voxel resolution 0.96 × 0.96 × 1.00 mm³. The planning CT scans were acquired on a Brilliance Big bore scanner (Philips Medical Systems, Best, The Netherlands), with a tube potential of 120 kVp, with use of a matrix size of 512 × 512 and 0.65 × 0.65 × 3.0 mm³ voxel size.

Imaging was used for three different methods: DBM, VBM and analysis of global tissue volumes (total GM, WM, CSF and TIV). For each of these methods, we analyzed the difference in volumes between baseline (pre-RT) and 1 year follow-up (post-RT). The latter was defined as the time point closest to 360 days after start of RT for which an MRI was available.

Image processing

Pre-RT and post-RT MRI scans were rigidly registered to each other, and to the planning CT and dose file. The MRI scans were processed automatically with the Computational Anatomy Toolbox (CAT12) [20]. First, MR images were rigidly co-registered to each other, followed by image de-noising and segmentation into GM, WM and CSF. Then, the MR images were non-linearly registered to standard stereotaxic MNI space [21] of 1.5 mm isotropic resolution and smoothed using an 8 mm kernel size. While spatial smoothing decreases the effective spatial resolution by incorporating information from neighboring voxels, it also increases the signal to noise ratio (SNR). The chosen 8 mm kernel presents a reasonable tradeoff and is in line with recommendations on how to perform VBM studies [22]. Considering that tumor beds and the surrounding tissues show morphological changes between MRI scans not necessarily related to the applied radiation, regions covered by the planning target volume (PTV) were censored during the analysis. The PTV for grade II consisted of the enhanced area on T2-FLAIR with a margin of 1.2 cm (CTV + PTV margins); for grade III-IV it was the gadolinium contrast enhancing tumor on T1-weighted MRI with a margin of 2.2 cm (CTV + PTV margins). This step prevents errors due to tissue misclassification at the tumor bed and in the surrounding tissues, and makes sure that the observed morphological changes are related to the applied radiation.

Deformation-based morphometry (DBM)

In DBM, the entire brain is analyzed, without pre-specifying the underlying tissue type. During non-linear registration of the individual brains to the standard template, different transformations are applied in each individual [11,12]. This results in 3D deformation fields, in which the local volume changes (expansions or contractions) are described by the Jacobian determinants. This way, the local volumes from each scan are retained in MNI space. By comparing the Jacobian determinants of the pre-RT and post-RT scans, relative volumetric changes after RT were determined for each voxel (Fig. 1A). Then, these changes were related to
the applied dose in EQD2.

**Voxel-based morphometry (VBM)**

In contrast to DBM, VBM is a tissue-specific analysis [15]. On both pre-RT and post-RT MRI scans, GM was automatically segmented as part of the processing pipeline (Fig. 2A). During VBM, the Jacobian determinants from the GM segmentations are used to investigate the modulated (volume preserved) GM changes. Relative changes in volume between the pre-RT and post-RT scans are obtained by comparing Jacobian determinants from the pre-RT and post-RT images, and then correlated to the associated MNI-warped dose maps for every patient.

**Statistical analysis**

Voxelwise and deformation-based statistical comparisons were carried out with a permutation test with 10,000 iterations performed with the permutation analysis of linear models (PALM) toolbox in Matlab [23–25]. Significance of a correlation was determined at $p_{\text{corr}} < 0.05$ using family-wise error rate (FWER) adjustment to correct for multiple comparisons, and 3D Threshold-Free Cluster Enhancement (TFCE) to boost the statistical power [26]. Age at the time of the diagnosis and sex of the patients were included as nuisance regressors. Tail approximation was used for faster calculations [27]. Significant DBM changes were expressed as relative volume changes per received radiation dose ($\%$/Gy), while significant VBM changes are expressed in $\text{mm}^3$/Gy. In order to report the brain regions in which dose-dependent volume loss occurred, we used the Neuromorphometrics brain atlas (Neuromorphometrics Inc., Somerville, Massachusetts, USA), part of the CAT12 toolbox [20]. This atlas divides the brain into 142 regions (of which 126 are GM), based on anatomy and function. The atlas includes all white matter, cerebral cortex, subcortical nuclei, and the ventricles, and allows us to identify the areas that are affected by radiation.

Differences in pre-RT and post-RT volume of GM, WM, CSF, and TIV were examined with a paired Wilcoxon signed rank test, with $p < 0.05$ as the threshold of statistical significance. This was also done for the ratio between total brain tissue volume (GM + WM) and TIV. Finally, in a post-hoc analysis the Pearson’s correlation coefficient was calculated for the relation between the PTV and the changes in total brain tissue volume.

**Results**

**Participants**

Of the 170 patients who underwent RT for glioma between in 2016 and 2017, 28 fulfilled our inclusion criteria and were selected for further analysis (Supplementary Fig. S1). Median age at baseline was 51 years, and 61% of patients had a high-grade glioma (Table 1). All patients were treated with volumetric modulated arc therapy (VMAT). Mean dose to the brain excluding PTV (the brain tissue used for analysis) ranged from 3.1 to 10.2 Gy, with a median of 7.1 Gy.

**DBM**

Areas of significant volume reduction with increasing dose 1 year after RT were seen throughout the brain as clusters of affected voxels (Fig. 1B). This loss of brain tissue consequently led to an increase in ventricle volume, which can be seen as clusters of voxels showing volume increase. Applying the Neuromorphometrics brain atlas revealed that, out of a total of 142 brain regions, 104 (73.2%) contained voxel clusters showing dose-dependent volume loss. Both WM and GM were affected, and within the latter both cerebral cortex and subcortical nuclei show volume loss. Volume loss rates ranging from at least 5.3 to

![Fig. 2. A. Example of grey matter (red mask) changes before and after radiotherapy (RT) as seen on T1-weighted MRI. B. Areas of significant relation between dose and volume change in all patients, as seen with voxel-based morphometry. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)](https://example.com/fig2.png)
maximal 15.3%/30 Gy were seen in the cerebral cortical regions in which more than 40% of voxels were affected (Supplementary Table 1). In the subcortical GM the bilateral hippocampus, thalamus, putamen and globus pallidus showed volume loss (Table 2) of at least 6.0% and maximal 17.5% per 30 Gy. The left and right cerebral white matter contained clusters both showing loss rates of 11.7%/30 Gy. Conversely, a significant lateral ventricular volume increase was observed, with a mean rate of 52.1%/30 Gy for the left and right lateral ventricle, which more than 40% of voxels were affected (Supplementary Table 1). Deformation-based analysis of the entire brain showed volume reduction in white matter, cerebral cortex, and subcortical grey matter. In this study, we found that the entire brain is susceptible to radiation induced morphological changes after RT for brain tumors. Total grey matter volume and total white matter volume were reduced by respectively 2.1% and 5.8%, with a compensatory increase in CSF volume. The observed rate of total brain volume change of 3.8% (combined GM and WM) is ten times higher than the normal annual atrophy rate of 0.33% [28]. Deformation-based analysis of the entire brain showed volume reductions in white matter, cerebral cortex, and subcortical grey matter. The GM was further analyzed with a voxel-based analysis, again showing susceptibility in a third of cortical regions and subcortical nuclei. Finding volume changes in three distinct types of analyses.

### Table 1
Baseline characteristics of included patients.

| N (total n = 28) |  
|------------------|
| Age (median; IQR) |  
| 51 (38–61) |  
| Sex |  
| Male | 17 (60.7%) |  
| Female | 11 (39.3%) |  
| WHO grade |  
| II | 11 (39.3%) |  
| III | 7 (25%) |  
| IV | 10 (35.7%) |  
| Tumor type |  
| Astrocytoma, IDH-mutant | 9 (32.1%) |  
| Astrocytoma, IDH-wildtype | 3 (10.7%) |  
| Oligodendroglioma, IDH-mutant | 3 (10.7%) |  
| Glioblastoma, IDH-wildtype | 10 (35.7%) |  
| Other | 3 (10.7%) |  
| Prescribed dose |  
| 28 × 1.8 – 50.4 Gy | 11 (39.3%) |  
| 30 × 1.8 – 54 Gy | 2 (7.1%) |  
| 30 × 2 – 60 Gy | 15 (53.6%) |  
| Treatment volumes in cc (median; IQR) |  
| GTV | 42.3 (20.9–92.5) |  
| CTV | 190.3 (138.3–200.8) |  
| PTV | 240.4 (188.0–364.7) |  
| Type of surgery |  
| Subtotal resection | 20 (71.4%) |  
| Biopsy | 8 (28.6%) |  
| Chemotherapy |  
| None | 4 (14.3%) |  
| Temozolomide | 20 (71.4%) |  
| PCV | 4 (14.3%) |  
| PCV = procarbazine, lomustine and vincristine |  

### Table 2
Significant dose-dependent changes in subcortical nuclei 1 year after radiotherapy, as shown with deformation-based morphometry.

| Region name | Affected voxels within area (%) | Relative volume change (%/30 Gy) | p-value |
|-------------|---------------------------------|----------------------------------|---------|
| Amygdala    | Left 0                          | –                                | –       |
|             | Right 20.8                       | 11.8                             | <0.01   |
| Caudate nucleus | Left 0                        | –                                | –       |
|             | Right 1.1                       | 8.6                              | 0.02    |
| Globus pallidus | Left 1.3                    | 8.8                              | <0.01   |
|             | Right 14.6                      | 10.0                             | 0.02    |
| Hippocampus | Left 21.5                       | 6.0                              | <0.01   |
|             | Right 4.3                       | 8.0                              | <0.01   |
| Nucleus accumbens | Left 0                        | –                                | –       |
|             | Right 0                         | –                                | –       |
| Putamen     | Left 18.6                       | 16.9                             | <0.01   |
|             | Right 21.8                      | 12.7                             | 0.02    |
| Thalamus    | Left 40.5                       | 17.5                             | <0.01   |
|             | Right 2.8                       | 12.0                             | <0.01   |

### Table 3
Brain regions in which more than 25% of voxels show volume decrease 1 year after radiotherapy, as shown with voxel-based morphometry

| Region name | Affected voxels within area (%) | Absolute volume change (mm³/Gy) | Relative volume change (%/30 Gy) | p-value |
|-------------|---------------------------------|---------------------------------|----------------------------------|---------|
| Left frontal | 61.0                            | 9.4                             | 16.1                             | <0.01   |
| operculum                            | 48.7                            | 9.2                             | 13.8                             | 0.01    |
| Left inferior orbital gyrus           | 47.2                            | 12.3                             | 12.9                             | <0.01   |
| insula                                | 35.1                            | 6.0                             | 6.1                              | <0.01   |
| Frontal gyrus                         | 31.1                            | 20.7                             | 21.2                             | <0.01   |
| Left Thalamus                         | 28.9                            | 2.8                             | 6.1                              | 0.02    |
| Proper                                | Left inferior                  | 25.7                            | 4.8                              | <0.01   |
| Frontal                               | orbital gyrus                   | 10.4                            | 13.8                             | 0.01    |
| Angular gyrus                         | Left frontal                   | 14.3                            | 13.8                             | 0.01    |
Clinical and Translational Radiation Oncology 31 (2021) 14–20

Clinical and Translational Radiation Oncology 31 (2021) 14–20

Table 4

| Region       | Median pre-RT volume (cc) | Median volume difference (cc) | 95% CI of difference | p    |
|--------------|---------------------------|-----------------------------|----------------------|------|
| TIV          | 1386.1                    | 2.2                         | −11.0 – 17.6         | 0.81 |
| GM           | 608.2                     | −12.8                       | −24.8 – −4.7         | <0.01|
| WM           | 520.6                     | −30.0                       | −42.0 – −20.1        | <0.01|
| CSF          | 288.0                     | 44.3                        | 21.3 – 75.5          | <0.01|

CSF = Cerebrospinal fluid; GM = Grey matter; TIV = Total intracranial volume; WM = White matter.

strengthens the evidence for a whole brain volume-reducing effect of radiotherapy.

This is not the first study looking into the morphological changes seen after RT for brain tumors. The group of Karumani et al. and Seibert et al. [7] were the first to show cortical susceptibility to dose-dependent thinning. Our recent study on this phenomenon confirmed these findings, and identified three cortical areas of heightened susceptibility, showing thinning rates after 30 Gy comparable to aging by a decade [5]. Subcortical structures such as hippocampus, amygdala, have also been shown to be vulnerable to volume changes after RT [9,10]. We have repeated these analyses, and observed comparable results [8]. Furthermore, we found that in addition to these two structures, the thalamus, globus pallidus, nucleus accumbens, and putamen also show an association between radiotherapy dose and post RT volume loss.

Connections have also been made between these morphological changes and observed cognitive decline, especially for hippocampal volume loss. Gondi et al. [29] showed an association between radiation dose and memory impairments, specifically regarding delayed recall performance. The effect of radiotherapy with or without hippocampal avoidance was further studied in a phase III trial [30]. Similar overall and progression-free survival were observed, but with lower risk of cognitive failure and better preservation of executive function, learning and memory.

Most of the abovementioned studies have investigated a specific part of the brain. However, the brain is a complex network of interconnected brain regions [31]. This is especially crucial when considering higher order cortical functions like cognition, which have been shown to rely on large-scale neural networks [32]. This means that analysis of only cerebral cortex or subcortical structures results in an incomplete picture of possible substrates of post-RT cognitive decline. We have therefore used DBM to analyze the entire brain (WM, cortex and subcortical nuclei), without prior specification of tissue type or location. This resulted in the finding that local susceptibility to radiation-induced damage is present throughout the brain. We conclude from this that a holistic approach to the discovery of etiology and possible prevention of cognitive decline is called for. We need to know the relation between dose and cognitive outcomes for the entire brain, not just for selected regions. Considering the fact that avoiding a structure like hippocampus leads to increased photon doses being delivered to other areas of the brain [33], we need to be sure these regions don’t have a similar susceptibility to radiation damage.

Because we do not have neurocognitive data on the studied patients, we have to look at morphological changes in other brain diseases to understand the implications of our results. Especially in Alzheimer’s disease, an association has been found between the volumes of cortical and subcortical GM and the development of cognitive impairments [34–38]. Additionally, the volumetric change in at least one GM structure has been linked to cognitive abilities in normal ageing [39], Parkinson’s disease [40–43], Huntington disease [44], and multiple sclerosis [45].

These results may make us reconsider the currently used organs at risk (OAR) in radiation treatment of brain tumors. Several institutions have implemented hippocampal avoidance whole-brain RT to prevent cognitive decline in patients with brain metastases. However, during the treatment plan optimization, higher doses are delivered to surrounding tissue when lowering dose in a specific structure [33]. We have found that this surrounding tissue can be similarly susceptible to radiation-induced damage. Future research should therefore study the relation between morphologic changes in the entire brain and cognitive outcomes. Then it can be conclusively deduced which structures should be considered OARs, and therefore should receive as little dose as possible, to limit or even prevent radiation-induced cognitive decline. Modern techniques such as VMAT and intensity modulated proton therapy (IMPT) could help us to specifically spare healthy brain tissue, should a relation between dose and cognition be found [46,47]. Avoiding critical brain structures could lead to better preservation of cognition and therefore improved quality of life in brain tumors patients after treatment.

In order to ensure that the results are not a by-product of false tissue estimation or tissue abnormalities, we applied a PTV-based censoring method. Well-recognized examples of possible false tissue misclassification are the tumor bed itself, and edema within the WM which could be misinterpreted for GM due to the changed intensities. In practice the censoring means that, while the whole images were used to calculate the native to MNI space transformations, the PTV labels were transformed as well. Then, the PTV-covered Jacobian determinants or transformed GM segmentations were ignored for the DBM and VBM analysis, respectively. It is also likely that the current censoring policy may be too conservative, and therefore produces some false negative results by censoring out too much non-abnormal tissue. One may reconsider GTV or CTV-based censoring or even manual delineation of the abnormal parts. However, the G/C/PTV regions are defined for every RT patient, and therefore does not require further manual interaction, which in turn improved the reproducibility of our results. As a consequence, the presented results are the minimally expected and safe results, considering changes only from the interaction of normal-appearing tissue and dose.

The biggest limitation to our study is the limited sample size. Due to the requirement of high quality T1 MRI scans before and after RT, only a small portion of scans were eligible for inclusion. We were therefore only able to study a linear effect between the two time points, while the true effect of dose on brain volumes may be non-linear (e.g. exponential or sigmoidal). The sample size could also be the cause of the significant results of VBM to be predominantly within the left hemisphere, as a non-uniform distribution of tumors within our data set may have skewed the results. However, this meticulously improves the reliability of our results, as they are unlikely to be affected by image quality.

Secondly, RT was not the only treatment received by patients in our cohort. Most also received surgical resection and concurrent or adjuvant chemotherapy, meaning that these treatments could also have affected the observed morphological changes. However, the baseline scans used for analysis were made after surgery, which means surgery is less likely to have an effect on the outcome. Chemotherapy, which has been shown to cause changes in brain tissue in non-neurological malignancies [48,49], could have had a diffused effect on brain tissue volumes. As we related the locally applied RT dose to brain morphology, we expect the role of chemotherapy to be limited.

Additionally, because of the presence of the tumor near the areas that receive the highest amount of dose, we cannot rule out that the tumor itself also has an effect on local changes in morphology. There already is evidence that shows that the tumor has an effect on neurocognition prior to treatment [50]. Another important factor when relating the applied dose to changes in brain volumes is the size of the PTV. With larger tumors, the PTV – and thereby the brain volume receiving higher doses – increases. This means that, in addition to effect from the tumor itself, the increased total brain dose in patients with larger tumors should be taken into account. In a post-hoc analysis, correlation of changes in total brain volume and the PTV size revealed a significant relation. Future studies with larger sample sizes should explore in which ways the relation between dose and volume change is affected by local tumor effects, tumor volume, and PTV size.
Finally, we do not have prospectively registered neurocognitive data on the patients in our cohort. This means we cannot conclude on clinical implications of the observed morphological changes, and therefore we cannot give strong recommendations to alter current RT strategies.

## Conclusion

We have found that radiotherapy dose is associated with morphological changes in the entire brain. Furthermore, these changes are linked to increased dose. This may lead us to consider revising the current avoidance strategies, as now only a limited number of areas are considered organs at risk, while our data suggests the whole brain volume should be taken into account. Before this can be done, more data on the relation between these morphological changes and cognitive and other neurological outcomes after radiotherapy are needed.

## Funding statement

Nothing to declare

## Data availability statement

As we have not obtained informed consent to share patient data, we cannot make our clinical data available.

## Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

## Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.ctro.2021.08.010.

## References

[1] Makale MT, McDonald CR, Hattangadi-Gluth JA, Kesari S. Mechanisms of radiation therapy-associated cognitive disability in patients with brain tumors. Nat Rev Neurol 2017;13(1):52-64. https://doi.org/10.1038/nrneurol.2016.185.

[2] Greene-Schloesser D, Robbins ME. Radiation-induced cognitive impairment from bench to bedside. Neuro-Oncology 2012;14(suppl 4):v37–44. https://doi.org/10.1093/neuonc/nos195.

[3] David S, Mesri HY, Bodiat VA, Nagtegaal SHJ, Elbahlawi H, de Luca A, et al. Dose-dependent degeneration of non-cancerous brain tissue in post-radiotherapy patients: A diffusion tensor imaging study. 19005157 MedRxiv 2019. https://doi.org/10.1101/19005157.

[4] Nagtegaal SHJ, David S, van der Boog ATJ, Leemans A, Verhoef JJC. Changes in cortical thickness and volume after cranial radiation treatment: A systematic review. Radiother Oncol 2019;135:33–42. https://doi.org/10.1016/j.radonc.2019.02.013.

[5] Nagtegaal SHJ, David S, Snijders TJ, Philippens MEP, Leemans A, Verhoef JJC. Effect of radiation therapy on cerebral cortical thickness in glioma patients: treatment-induced thinning of the healthy cortex. Neuro-Oncol Adv 2020;2:1–9. https://doi.org/10.1093/noaav050.

[6] Karunamuni R, Barlow MS, Moiseenko V, Cammona R, Marshall DC, et al. Dose-dependent cortical thinning after partial brain irradiation in high-grade glioma. Int J Radiat Oncol Biol Phys 2016;94(2):297–304. https://doi.org/10.1016/j.ijrobp.2015.10.014.

[7] Zeller B, Tammes CK, Kanellopoulos A, Amlien IK, Andersson S, Due-Tønnessen P, et al. Reduced neuroanatomic volumes in long-term survivors of childhood acute lymphoblastic leukemia. J Clin Oncol 2013;31(17):2078–85. https://doi.org/10.1200/jco.2012.47.4031.

[8] Ashburner J, Friston KJ. Voxel-based morphometry: The methods. Neuroimage 2000;11(6):805–21. https://doi.org/10.1016/j.neuroimage.2000.0582.

[9] Ashburner J, Friston KJ. Unified segmentation. Neuroimage 2005;26(3):839–51. https://doi.org/10.1016/j.neuroimage.2005.02.018.

[10] Banke K, Dahnke R, Clarke G, Li A, Li C, Nathaniel P, et al. MRI based biomarker for brain aging in rodents and non-human primates. In: PRIN 2016–6th International Workshop on Pattern Recognition in Neuroimaging, Institute of Electrical and Electronics Engineers Inc; 2016. https://doi.org/10.1109/PRIN.2016.7552226.

[11] Steinke J, Gaser C, Langbein K, Dietzek M, Gusev A, Reichenbach JR, et al. Hippocampal metabolism and prefrontal brain structure: A combined 1H-MR spectroscopy, neuropsychological, and voxel-based morphometry (VBM) study. Brain Image Res 2017;6:177–94. https://doi.org/10.1016/j.birn.2017.09.024.

[12] Zeller B, Tammes CK, Kanellopoulos A, Amlien IK, Andersson S, Due-Tønnessen P, et al. Reduced neuroanatomic volumes in long-term survivors of childhood acute lymphoblastic leukemia. J Clin Oncol 2013;31(17):2078–85. https://doi.org/10.1200/jco.2012.47.4031.

[13] Gaser C, Dahnhke R. CAT-a computational anatomy toolbox for the analysis of structural MRI data. Ibm 2016:1633–48. https://doi.org/10.1200/JCO.2016.68.12.008.

[14] Collins DL, Neelin P, Peters TM, Evans AC. Automatic 3d intersubject registration of our volumetric data in standardized talairach space. J Comput Assist Tomogr 1994;18(2):192–205. https://doi.org/10.1097/00004728-199403000-00005.

[15] Kurth F, Gaser C, Luders E. A 12-step user guide for analyzing voxel-wise gray matter asymmetries in statistical parametric mapping (SPM). Nat Protoc 2015;10 (2):293–304. https://doi.org/10.1038/nprot.2015.014.

[16] Winkler AM, Ridgway GR, Webster MA, Smith SM, Nichols TE. Permutation inference for the general linear model. Neuroimage 2014;92:381–97. https://doi.org/10.1016/j.neuroimage.2014.01.060.

[17] Nichols T, Holmes A. Nonparametric permutation tests for functional neuroimaging. Hum Brain Map 2002;6:39–42. https://doi.org/10.1002/00004647.19961001.00002.

[18] Gondi VP, Hermann BP, Mehta MP, Tome WA, Tome WA. Hippocampal dosimetry predicts neurocognitive function impairment after fractionated stereotactic radiotherapy for benign or low-grade adult brain tumors. J Neurosurg Oncol 2013;83:e47–93. https://doi.org/10.1093/jno/njs004.

[19] Smith SM, Nichols T. Threshold-free cluster enhancement: Addressing problems of smoothing, threshold dependence and localisation in cluster inference. Neuroimage 2009;44(1):83–98. https://doi.org/10.1016/j.neuroimage.2008.03.061.

[20] Winkler AM, Ridgway GR, Donaer G, Nichols TE, Smith SM. Faster permutation inference in brain imaging. Neuroimage 2016;141:502–16. https://doi.org/10.1016/j.neuroimage.2016.05.066.

[21] Scabill RI, Frost C, Jenkins R, Whitwell JL, Rorsou MN, Fox NC. A longitudinal study of brain volume changes in normal aging using serial registered magnetic resonance imaging. Arch Neurol 2003;60:989–94. https://doi.org/10.1001/archneurol.60.7.989.

[22] Gondi VP, Hermann BP, Mehta MP, Tome WA, Tome WA. Hippocampal dosimetry predicts neurocognitive function impairment after fractionated stereotactic radiotherapy for benign or low-grade adult brain tumors. J Neurosurg Oncol 2013;83:e47–93. https://doi.org/10.1093/jno/njs004.

[23] Brown PD, Gondi V, Pugh S, Tome WA, Wefel JS, Armstrong TS, et al. Hippocampal avoidance during whole-brain radiotherapy plus memantine for patients with brain metastases: phase II trial NRG oncology CCO01. J Clin Oncol 2020;38(10): 1019–29. https://doi.org/10.1200/jco.2019.02767.

[24] Bassett DS, Gazzainga MS. Understanding complexity in the human brain. Trends Cogn Sci 2011;15(5):200–9. https://doi.org/10.1016/j.tics.2011.03.006.

[25] Breder SL, Toogood J, Operational principles of neurocognitive networks. Int J Psychophysiol 2006;60(2):139–48. https://doi.org/10.1016/j.ijpsycho.2005.12.008.

[26] Verma V, Robinson GG. Hippocampal-sparing radiotherapy for patients with glialomas and grade II-III gliomas. JAMA Oncol 2020;6(7):981. https://doi.org/10.1001/jamaoncol.2020.0164.

[27] de Jong LW, van der Hiele K, Veer IM, Houwing JJ, Westendorp RGJ, Bollen ELEM, et al. Strongly reduced volumes of putamen and thalamus in Alzheimer’s disease: an MRI study. Brain 2008;131(12):3277–85. https://doi.org/10.1093/brain/awn278.

[28] Nie X, Sun Y, Sas H, Liu R, Li X, et al. Subregional structural alterations in hippocampus and nucleus accumbens correlate with the clinical impairment in patients with Alzheimer’s disease clinical spectrum: parallel combining volume...
and vertex-based approach. Front Neurol 2017;8. https://doi.org/10.3389/fneur.2017.00399.

[36] Yi H-A, Möller C, Dieleman N, Bouwman FH, Barkhof F, Scheltens P, et al. Relation between subcortical grey matter atrophy and conversion from mild cognitive impairment to Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2016;87(4):425–32. https://doi.org/10.1136/jnnp-2014-309105.

[37] Du A-T, Schiff N, Kramer JH, Rosen HJ, Gorno-Tempini ML, Rankin K, et al. Different regional patterns of cortical thinning in Alzheimer’s disease and frontotemporal dementia. Brain 2007;130(4):1159–66. https://doi.org/10.1093/brain/aws016.

[38] Yin C, Li S, Zhao W, Feng J. Brain imaging of mild cognitive impairment and Alzheimer’s disease. Neural Regener Res 2013;8:435–44. https://doi.org/10.3969/j.issn.1673-5374.2013.05.007.

[39] Hughes EJ, Bond J, Svrckova P, Makropoulos A, Ball G, Sharp DJ, et al. Regional changes in thalamic shape and volume with increasing age. Neuroimage 2012;63 (3):1134–42. https://doi.org/10.1016/j.neuroimage.2012.07.043.

[40] Hangana A, Bedetti C, Degroot C, Mejia-Constain B, Lafontaine A-L, Soland V, et al. Mild cognitive impairment is linked with faster rate of cortical thinning in patients with Parkinson’s disease longitudinally. Brain 2014;137:1120–9. https://doi.org/10.1093/brain/aws036.

[41] Hüneler D, Emek-Savaş DD, Çavuşoğlu B, Dönmez Çalışkaoğlu B, Ada E, Yener GG, Mild cognitive impairment in Parkinson’s disease is associated with decreased P300 amplitude and reduced putamen volume. Clin Neurophysiol 2019;130(8):1208–17. https://doi.org/10.1016/j.clinph.2019.04.314.

[42] García-Díaz AI, Segura B, Baggio HC, Uribe C, Campabalaal A, Abos A, et al. Cortical thinning correlates of changes in visuospatial and visuoperceptual performance in Parkinson’s disease: a 4-year follow-up. Parkinsonism Related Disorders 2018;46:62–8. https://doi.org/10.1016/j.parkreldis.2017.11.003.

[43] Pereira JB, Ibarretxe-Bilbao N, Martí M-J, Compta Y, Junqué C, Bargallo N, et al. Assessment of cortical degeneration in patients with Parkinson’s disease by voxel-based morphometry, cortical folding, and cortical thickness. Hum Brain Mapp 2012;33(11):2521–34. https://doi.org/10.1002/hbm.21378.

[44] Aylward EH, Harrington DL, Mills JA, Nopoulos PC, Ross CA, Long JD, et al. Regional atrophy associated with cognitive and motor function in prodromal Huntington disease. J Huntington’s Dis 2013;2:477–89. https://doi.org/10.3233/JHD-130076.

[45] Rojas JI, Murphy G, Sanchez F, Patrucco L, Fernandez MC, Miguel J, et al. Thalamic volume change and cognitive impairment in early relapsing-remitting multiple sclerosis patients. Neuroradiol J 2018;31(4):350–5. https://doi.org/10.1007/s12658-018-0270-2.

[46] Gronhans DR, Mohan R, Gondi V, Shih HA, Mahajan A, Brown PD. The role of image-guided intensity modulated proton therapy in glioma. Neuro-Oncology 2019;21:130–7. https://doi.org/10.1093/neuonc/noz002.

[47] Sood S, Pokhrel D, McClintic C, Lominska C, Badkul R, Jiang H, et al. Volumetric-modulated arc therapy (VMAT) for whole brain radiotherapy: not only for hippocampal sparing, but also for reduction of dose to organs at risk. Med Dosim 2017;42(4):375–83. https://doi.org/10.1016/j.meddos.2017.07.005.

[48] Bernad D, Collins L, Fiocco A, Gr M, Shenouda G, Panet-Raymond V, et al. Analysis of structural changes in hippocampal and amygdala volume after systemic therapy and prophylactic cranial irradiation in patients with limited stage-small cell lung cancer. Int J Radiat Oncol Biol Phys 2013;87:S103. https://doi.org/10.1016/j.ijrobp.2013.06.267.

[49] Henneghan A, Rao Y, Harrison RA, Karuturi M, Blayney DW, Palesh O, et al. Cortical brain age from pre-treatment to post-chemotherapy in patients with breast cancer. Neurotox Res 2020;37(4):788–99. https://doi.org/10.1007/s12640-019-00158-z.

[50] Van Kessel E, Emons MAC, Wajer IH, Van Baarsen KM, Broekman ML, Robe PA, et al. Tumor-related neurocognitive dysfunction in patients with diffuse glioma: A retrospective cohort study prior to antitumor treatment. Neuro-Oncol Practice 2019;6:463–72. https://doi.org/10.1093/nop/npx008.